Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
General Pharmaceutical Council issues new guidance following reports people are lying about their weight in online forms and submitting photos of themselves in baggy clothes ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
Futurism on MSN3d
Pharmacists Warn That People With Eating Disorders Are Misusing Wegovy PrescriptionsMore and more people are taking weight loss injectables like Wegovy and Mounjaro — and pharmacy experts are worried that not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback